四味余甘子方对高脂血症大鼠抗过氧化及血脂水平的影响  

Effects of Siweiyuganzi prescription on anti-peroxidation and blood lipid levels in rats with hyperlipidemia

作　　者：杨如意[1] 周盼盼 王宏斌 曹昌霞[1] 徐海珍[1] 刘永萍[1] 赵文玲[1] 孙兆[1] 王君[1] Yang Ruyi;Zhou Panpan;Wang Hongbin;Cao Changxia;Xu Haizhen;Liu Yongping;Zhao Wenling;Sun Zhao;Wang Jun(Department of Integration of Traditional Chinese and Western Medicine,Affiliated Hospital of Qinghai University,Xining 810001,Qinghai,China;Medical College of Qinghai University,Xining 810016,Qinghai,China)

机构地区：[1]青海大学附属医院中西医结合科,青海西宁810001 [2]青海大学医学院,青海西宁810016

出　　处：《中国中西医结合急救杂志》2019年第4期389-392,共4页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：青海省科技计划项目(2017-ZJ-737).

摘　　要：目的观察藏药复方四味余甘子方对实验性高脂血症模型大鼠抗过氧化和血脂水平的影响.方法选择雄性SD大鼠60只,按随机数字表法分为正常对照组、高脂血症模型组、血脂康组、四味余甘子方大、中、小剂量组,每组10只.采用灌服10mL·kg^-1·d^-1高脂乳剂的方法复制高脂血症动物模型.正常对照组和高脂血症模型组灌胃生理盐水10mL/kg、每日2次;四味余甘子方组以12.8、6.4、4.3g·kg^-1·d^-13个剂量灌胃;血脂康组灌胃0.3g·kg^-1·d^-1血脂康混悬液.4周后,观察各组血脂和血清超氧化物歧化酶(SOD)、丙二醛(MDA)、羟甲基戊二酰辅酶A(HMG-CoA)还原酶水平的变化.结果与正常对照组比较,高脂血症模型组血清三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、MDA、HMG-CoA含量和肝组织HMG-CoA阳性表达、丙氨酸转氨酶(ALT)水平均明显升高〔TG(mmol/L):6.59±0.72比4.32±0.36,TC(mmol/L):7.10±0.25比5.98±0.40,LDL-C(mmol/L):4.18±1.30比2.33±0.35,MDA(μmol/L):26.05±5.99比10.08±1.98,HMG-CoA含量(ng/L):54.60±2.90比48.73±3.09,HMG-CoA阳性表达:(57.80±12.30)%比(22.00±4.92)%,ALT(U/L):106.83±15.75比81.97±13.18〕,SOD、高密度脂蛋白胆固醇(HDL-C)明显降低〔SOD(kU/L):295.47±37.51比345.13±19.76,HDL-C(mmol/L):2.32±0.49比4.84±0.45,均P<0.05〕.与高脂血症模型组比较,各给药组TG、TC、LDL-C、MDA和HMG-CoA含量以及肝组织阳性表达均明显降低,SOD、HDL-C均明显升高,且以四味余甘子方大剂量组的变化较四味余甘子方中、小剂量组更显著〔TG(mmol/L):4.70±0.46比5.40±0.31、5.70±0.41,TC(mmol/L):5.80±0.23比6.14±0.20、6.56±0.32,LDL-C(mmol/L):2.56±0.45比2.93±0.33、3.28±0.32,HDL-C(mmol/L):4.58±0.28比3.89±0.30、3.59±0.08,SOD(kU/L):381.45±20.68比360.60±30.16、325.49±32.13,MDA(μmol/L):16.98±5.39比17.89±5.37、21.03±6.01,HMG-CoA含量(ng/L):50.58±0.77比52.16±0.66、52.90±0.91,肝组织HMG-CoA阳性表达:(27.90±6.03)%比(32.20±7.00)Objective To observe the effects of Siweiyuganzi prescription on anti-peroxidation and blood lipid levels in experimental rats with hyperlipidemia.Methods Sixty male Sprague-Dawley(SD)rats were divided into normal control group,hyperlipidemia model group,Xuezhikang group,Siweiyuganzi prescription large,medium and small dose group according to the random number table method,with 10 rats in each group.The hyperlipidemia rat model was established by intragastric feeding with high fat emulsion everyday 10 mL·kg^-1·d^-1;normal saline 10 mL/kg was given to the normal control group,twice a day by intragastric feeding;3 dosages of Siweiyuganzi suspended fluid 12.8,6.4,4.3 g·kg^-1·d^-1 intragastric administrations were given to Siweiyuganzi prescription large,medium and small dose groups respectively;Xuezhikang suspended fluid 0.3 g·kg^-1·d^-1 was given to Xuezhikang group intragastrically;the same volume of normal saline was given to hyperlipidemia model group.After 4 weeks,the level changes of blood lipid,serum superoxide dismutase(SOD),malonaldehyde(MDA),hydroxymethylglutaryl Coenzyme A(HMG-CoA)were observed.Results Compared to those in the normal control group,the levels of triglyceride(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),MDA,content and positive expression of HMG-CoA,alanine aminotransferase(ALT)were all higher in hyperlipidemia model group[TG(mmol/L):6.59±0.72 vs.4.32±0.36,TC(mmol/L):7.10±0.25 vs.5.98±0.40,LDL-C(mmol/L):4.18±1.30 vs.2.33±0.35,MDA(μmol/L):26.05±5.99 vs.10.08±1.98,HMG-CoA content(ng/L):54.60±2.90 vs.48.73±3.09,HMG-CoA positive expression in liver tissue:(57.80±12.30)%vs.(22.00±4.92)%,ALT(U/L):106.83±15.75 vs.81.97±13.18];SOD and high-density lipoprotein cholesterol(HDL-C)in hyperlipidemia model group were significantly decreased[SOD(kU/L):295.47±37.51 vs.345.13±19.76,HDL-C(mmol/L):2.32±0.49 vs.4.84±0.45,both P<0.05].Compared with the hyperlipidemia model group,the TG,TC,LDL-C,MDA,contents and positive expression of HMG-CoA in each group were si

关 键 词：高脂血症 四味余甘子方 超氧化物歧化酶 丙二醛 大鼠 

分 类 号：R972.6[医药卫生—药品]